SCHEMBL19176641

SCHEMBL19176641

CCCS(=O)(=O)N[C@@H]1CCN(C(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.42
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
HCRTR2 O43614 1/20 0.35
HRH3 Q9Y5N1 5/20 0.34
SLC6A5 Q9Y345 1/20 0.32
SLC6A9 P48067 1/20 0.32
KCNH2 Q12809 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
DRD3 P35462 1/20 0.32
FGFR4 P22455 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 2/20 0.31
UCHL1 P09936 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102745 0.90 F10 (0.49) F10PSEN1PSEN2APH1BNCSTN
SCHEMBL19176850 0.89 F10 (0.39) F10HCRTR2HRH3SLC6A5HTR1A
SCHEMBL16078083 0.79 PSEN1 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL10218749 0.78 F10 (0.46) F10HCRTR2HRH3HTR1AALDH1A1
SCHEMBL17776663 0.78 AKT1 (0.39) F10HRH3SLC6A5ALDH1A1UCHL1
SCHEMBL12026505 0.78 AKT1 (0.39) F10HRH3SLC6A5ALDH1A1UCHL1
SCHEMBL2758661 0.77 HRH3 (0.37) F10HRH3SLC6A5KCNH2ALDH1A1
SCHEMBL22057184 0.77 CA1 (0.42) F10HRH3SLC6A5ALDH1A1UCHL1
SCHEMBL14024981 0.77 HRH3 (0.37) F10HRH3SLC6A5KCNH2ALDH1A1
SCHEMBL19176965 0.77 HRH3 (0.37) F10HRH3SLC6A5KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11498926-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2022-11-15 US disclosed
US-20210188872-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORTION 2021-06-24 US disclosed
US-9938294-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2018-04-10 US disclosed
US-20170210754-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE HOLDINGS CORPORATION (US) 2017-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188872-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 F10 3348/4885PSEN1 1604/4885PSEN2 1805/4885
US-20170210754-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 F10 3715/4885PSEN1 2219/4885PSEN2 2049/4885
US-11498926-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 F10 3348/4885PSEN1 1604/4885PSEN2 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.